A premier global contract research organization (CRO) providing essential animal models and laboratory services to accelerate drug discovery and development for life sciences clients.
CRL offers exposure to the growing demand for preclinical research services as life sciences companies continue to invest heavily in R&D despite macroeconomic headwinds. The company's diverse geographic footprint and specialized asset base provide resilience against regional downturns, positioning it well for long-term recovery once client spending normalizes.
The stark deterioration from a $480M profit in 2023 to a $142M loss in 2025 raises serious concerns about the sustainability of current business models and potential hidden liabilities. With a retained earnings deficit of $1.39B and negative net income trends, investors face elevated risk of continued earnings volatility and potential dilution if equity financing becomes necessary.
Charles River Laboratories International (CRL) is a leading global provider of contract research services for the life sciences industry, specializing in animal models, laboratory animals, and clinical trial support. The company serves major pharmaceutical, biotechnology, agricultural, and medical device companies across its North American, European, and Asian operations. Key offerings include specialized rodent colonies, non-human primate facilities, and comprehensive toxicology and safety testing.
Despite generating $4.02B in revenue similar to previous years, the company reported a net loss of $142.2M in 2025 compared to a profit of $25.3M in 2024, indicating severe margin compression or one-time charges not reflected in gross profit alone. The cash flow from operations remains robust at $737.6M, yet the company spent over $1.2B on debt issuances and $360.7M on share repurchases, suggesting aggressive capital management amidst deteriorating earnings quality.
The global contract research services industry is expanding as pharmaceutical companies outsource non-core functions to focus on innovation, though it faces headwinds from rising operational costs and a shift toward AI-driven drug discovery. CRL operates in a niche where high barriers to entry regarding specialized facilities and regulatory knowledge protect margins, but client budgets are increasingly under pressure.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $3.98B | $4.13B | $4.05B | $4.02B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $3.98B | $4.13B | $4.05B | $4.02B |
| Operating Expenses | $3.33B | $3.51B | $3.82B | $3.99B |
| Operating Income | $651.0M | $617.3M | $227.3M | $25.2M |
| G&A | $665.1M | $747.9M | $751.0M | $743.1M |
| Stock-Based Comp | $73.6M | $72.0M | $69.9M | $71.1M |
| D&A | $303.9M | $314.1M | $361.7M | $403.3M |
| Depreciation | $157.3M | $176.7M | $190.2M | $177.6M |
| Amortization | $146.6M | $137.4M | $138.5M | $179.1M |
| Other OpEx | $2.66B | $2.76B | $3.07B | $3.25B |
| Non-Operating Income | $-28.0M | $-36.0M | $-134.2M | $-124.7M |
| Interest Expense | $59.3M | $136.7M | — | — |
| Interest Income | $780.0K | $5.2M | $8.6M | $4.9M |
| Pre-Tax Income | $623.0M | $581.3M | $93.1M | $-99.5M |
| Income Tax | $130.4M | $100.9M | $67.8M | $42.7M |
| Continuing Ops | $492.6M | $480.4M | $25.3M | $-142.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $492.6M | $480.4M | $25.3M | $-142.2M |
| Minority Interest | $6.4M | $5.7M | $3.1M | $2.2M |
| Net to Common | $486.2M | $474.6M | $22.2M | $-144.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.44B | $1.61B | $1.40B | $1.45B |
| Cash & Equivalents | $233.9M | $276.8M | $194.6M | $213.8M |
| Accounts Receivable | $752.4M | $780.4M | $720.9M | $708.9M |
| Inventory | $255.8M | $380.3M | $278.5M | $299.1M |
| Prepaid Expenses | $107.6M | $83.4M | $105.8M | $129.2M |
| Other Current Assets | $89.3M | $87.9M | $103.2M | $96.1M |
| Long-Term Assets | $6.16B | $6.59B | $6.13B | $5.69B |
| PP&E (Net) | $1.47B | $1.64B | $1.60B | $1.66B |
| Goodwill | $2.85B | $3.10B | $2.85B | $2.76B |
| Operating Leases | $391.8M | $394.0M | $412.5M | $361.4M |
| Other LT Assets | $1.14B | $1.21B | $1.04B | $700.5M |
| Total Assets | $7.60B | $8.20B | $7.53B | $7.14B |
| Current Liabilities | $1.09B | $1.06B | $994.1M | $1.12B |
| Accounts Payable | $205.9M | $168.9M | $140.3M | $148.8M |
| Current Debt | $1.3M | $3.2M | $155.0K | $166.0K |
| Current Leases | $46.5M | $54.9M | $54.2M | $57.7M |
| Deferred Revenue | $264.3M | $241.8M | $248.3M | $210.4M |
| Other Current Liab | $353.8M | $358.4M | $319.1M | $433.2M |
| Long-Term Liabilities | $3.49B | $3.48B | $3.03B | $2.80B |
| LT Operating Leases | $389.7M | $419.2M | $483.8M | $434.0M |
| Other LT Liab | $3.10B | $3.06B | $2.54B | $2.37B |
| Total Liabilities | $4.58B | $4.54B | $4.02B | $3.92B |
| Shareholders' Equity | $3.02B | $3.66B | $3.51B | $3.21B |
| Retained Earnings | $1.43B | $1.89B | $1.81B | $1.39B |
| AOCI | $-262.1M | $-196.4M | $-317.3M | $-171.8M |
| Total L&E | $7.60B | $8.20B | $7.53B | $7.14B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $492.6M | $480.4M | $25.3M | $-142.2M |
| Non-Cash Adjustments | $-81.7M | $176.2M | $719.0M | $791.2M |
| Working Capital Changes | $208.7M | $27.4M | $-9.8M | $88.6M |
| Cash from Operations | $619.6M | $683.9M | $734.6M | $737.6M |
| Cash from Investing | $-607.9M | $-563.2M | $-245.1M | $-209.3M |
| Debt Issuances | $2.95B | $776.4M | $1.08B | $1.23B |
| Share Buybacks | $38.7M | $24.2M | $119.2M | $360.7M |
| Cash from Financing | $-42.4M | $-85.5M | $-550.9M | $-536.7M |
| FX Effect | $25.6M | $8.0M | $-17.5M | $18.8M |
| Net Change in Cash | $-5.1M | $43.3M | $-78.9M | $10.4M |
| Beginning Cash | $246.3M | $241.2M | $284.5M | $205.6M |
| Ending Cash | $241.2M | $284.5M | $205.6M | $216.0M |
The company's revenue is primarily driven by its Laboratory Animals segment, which supplies specialized rodent colonies and non-human primate resources, alongside its Clinical Research Services segment offering toxicology, safety pharmacology, and clinical trial support. Operations are geographically diversified across North America, Europe, and Asia, with significant contributions from its Animal Models business in generating high-margin research tools.
Significant concentration risk exists as a single large client can materially impact annual revenue and profitability given the cyclical nature of pharmaceutical R&D spending. Regulatory changes in animal testing standards or shifts toward non-animal models could disrupt core revenue streams, while geopolitical tensions may complicate cross-border clinical trial operations.
CRL maintains a deep moat through its proprietary collection of genetically modified animal models and specialized non-human primate colonies that are difficult for competitors to replicate quickly. The company benefits from strong client retention due to the high switching costs associated with complex, long-term drug development programs requiring consistent regulatory compliance and specialized facility expertise.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.